Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tcr2 Therapeutics Inc (NQ: TCRR )

1.450 +0.010 (+0.69%)
Streaming Delayed Price Updated: 9:30 AM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tcr2 Therapeutics Inc

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
From Brodsky & Smith LLC
Via Globe NewsWire
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via Globe NewsWire
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
From Kahn Swick & Foti, LLC
Via Business Wire
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of 
Via Spotlight Growth
TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors... 
Via Newsfile
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Announces Pipeline Priorities for 2023
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via Globe NewsWire
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
From TCR2 Therapeutics
Via Globe NewsWire
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
From TCR2 Therapeutics
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.